http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Gi Ppeum Han,Sung Hoon Kwon,Chan Ho Kwon,Deok Yun Kim,Dong Yong Kil 경상대학교 농업생명과학연구원 2023 농업생명과학연구 Vol.57 No.3
The objective of the present experiment was to investigate the effects of dietary vitamin C (VC), vitamin E (VE), and betaine (BT) supplementations on productive performance, egg quality, relative organ weights, liver visual characteristics, antioxidant status, immune response, and stress indicator in laying hens raised under heat stress conditions. A total of 280 47-wk-old Hy-Line Brown laying hens were allotted to 1 of 4 dietary treatments with 7 replicates in a completely randomized design. Each replicate had 10 birds per cage. The basal diet was formulated to meet or exceed the requirement estimates for Hy-Line Brown laying hens. Three additional diets were prepared by adding 250 mg/kg VC, 250 mg/kg VE, or 3,000 mg/kg BT to the basal diet. The experimental diets and water were provided to hens on an ad libitum basis for 8 wk. Average daily room temperature and relative humidity were 30.7±1.41℃ and 72.5±11.61%, respectively. Results indicated that hens fed diets containing 250 mg/kg VE had a less (p<0.05) egg production rate than other dietary treatments. For egg quality, hens fed diets containing 3,000 mg/kg BT had a less (p<0.05) eggshell thickness than those fed the diets containing 250 mg/kg VC or 250 mg/kg VE. For antioxidant status, there was a tendency (p=0.09) for the least malondialdehyde (MDA) concentrations in the liver for BT treatment. A tendency (p=0.05) was observed for less blood heterophil:lymphocyte ratio in BT treatment as compared to other treatments. In conclusion, dietary supplementation of 250 mg/kg VC, 250 mg/kg VE, and 3,000 mg/kg BT has no beneficial effects on productive performance, egg quality, relative organ weights, liver visual characteristics, and immune responses of laying hens raised under the current heat stress conditions. However, dietary supplementation of 3,000 mg/kg BT alleviates antioxidant status and stress response of laying hens exposed to heat stress.
Case Report : Asymptomatic renal pseudoaneurysm after percutaneous renal biopsy
( Gi Young Yun ),( Seung Kyo Kim ),( Seung Kyo Park ),( Sung Jin Moon ),( Jung Eun Lee ),( Suk Won Song ),( Kwang Hun Lee ),( Hyeong Cheon Park ),( Sung Kyu Ha ),( Hoon Young Choi ) 대한신장학회 2013 Kidney Research and Clinical Practice Vol.32 No.2
A 37-year-old man was referred to Division of Nephrology for a new renal cystic lesion that was found on ultrasonography. Four years prior to presentation, a percutaneous renal biopsy had been performed. Computed tomography scan showed a 4.4-cm-sized renal artery pseudoaneurysm in the left kidney. Selective renal angiography revealed a pseudoaneurysm in the left lower pole of the kidney. The renal pseudoaneurysmwas successfully embolized with coil. Follow-up Doppler ultrasonography showed no internal blood ?ow into the aneurysmal sac. His renal function remained stable after coil embolization.
( Gi Ae Kim ),( Young Suk Lim ),( Ju Hyun Shim ),( Kang Mo Kim ),( Han Chu Lee ),( Yung Sang Lee ),( Young Hwa Chung ),( Dan Bi Lee ),( Jih Yun An ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Spontaneous or interferon-induced HBsAg seroclearance is durable in most patients with chronic hepatitis B (CHB). However, little is known about the durability of HBsAg seroclearance following nucleoside analogue (NUC) therapy. Methods: Among 4,578 patients who were treated with either lamivudine (n=1,924) or entecavir (n=2,654) at a tertiary referral hospital in Korea between 2000 and 2010, 121 achieved HBsAg seroclearance. Fifty-eight patients were included in this study after exclusion of 63 patients; acute hepatitis B (n=19), hepatocellular carcinoma (n=8), prior treatment with interferon (n=6), prior immunosuppressive therapy (n=17), liver transplantation (n=6), follow-up loss immediately after HBsAg seroclearance (n=5), and continued NUC therapy (n=2). Results: Mean age of 58 patients were 42 (SD 11) years and 41 (71%) were males. All were assumed to have HBV genotype C. At the initiation of NUC therapy, median levels of ALT and HBV DNA were 153 IU/L (interquartile range [IQR], 48-340 IU/L) and 7.0 log10 copies/mL (IQR, 3.8-8.0 log10 copies/mL), respectively. Twenty-seven (47%) had HBeAg. The median duration of NUC therapy (56 with lamivudine and 2 with entecavir) before HBsAg seroclearance was 42 months (IQR, 24-66 months). During a median follow-up period of 20 months (IQR, 12-32 months), HBsAg reversion occurred in 5 of 58 (8.6%) patients. Three of those 5 patients achieved re-clearance of HBsAg without treatment during further follow-up. The other 2 patients remained HBsAg-positive, but with low titer (<1.0 IU/mL) and undetectable HBV DNA by PCR. Virologic recurrence (detectable HBV DNA by PCR) occurred in 12 of 58 (20.7%) patients. However, all of these patients maintained HBV DNA <10,000 copies/mL. No patient experienced biochemical relapse (ALT flare > x5 ULN). Conclusion: HBsAg seroclearance following NUC therapy is rare but durable in most patients with CHB after treatment discontinuation. Therefore, HBsAg seroclearance would be an ideal treatment endpoint during NUC therapy.
Yun-Beom Sim,Soo-Hyun Park,Yu-Jung Kang,Sung-Su Kim,Chea-Ha Kim,Su-Jin Kim,Su-Min Lim,Jun-Sub Jung,Ohk-Hyun Ryu,Moon-Gi Choi,Hong-Won Suh 대한생리학회-대한약리학회 2013 The Korean Journal of Physiology & Pharmacology Vol.17 No.6
We have recently demonstrated that some anti-diabetic drugs such as biguanide and thizolidi-nediones administered centrally modulate the blood glucose level, suggesting that orally administered anti-diabetic drugs may modulate the blood glucose level by acting on central nervous system. The present study was designed to explore the possible action of another class of anti-diabetic drugs, glinidies, administered centrally on the blood glucose level in ICR mice. Mice were administered intracerebroventricularly (i.c.v.) or intrathecally (i.t.) with 5 to 30 μg of repaglinide or nateglinide in D-glucose-fed and streptozotocin (STZ)-treated models. We found that i.c.v. or i.t. injection with repaglinide dose-dependently attenuated the blood glucose level in D-glucose-fed model, whereas i.c.v. or i.t. injection with nateglinide showed no modulatory action on the blood glucose level in D-glucose-fed model. Furthermore, the effect of repaglinide administered i.c.v. or i.t. on the blood glucose level in STZ-treated model was studied. We found that repaglinide administered i.c.v. slightly enhanced the blood glucose level in STZ-treated model. On the other hand, i.t. injection with repaglinide attenuated the blood glucose level in STZ-treated model. The plasma insulin level was enhanced by repaglinide in D-glucose-fed model, but repaglinide did not affect the plasma insulin level in STZ-treated model. In addition, nateglinide did not alter the plasma insulin level in both D-glucose-fed and STZ-treated models. These results suggest that the anti-diabetic action of repaglinide appears to be, at least, mediated via the brain and the spinal cord as revealed in both D-glucose fed and STZ-treated models.